Genome-wide screen finds host-targeted drugs and SARS-CoV-2 pro-viral pathways

A new study published in npj Viruses reports that a genome-wide host-directed screening strategy can uncover both antiviral drug candidates and cellular signalling routes hijacked by SARS-CoV-2. The work by Khan and colleagues uses the host genome as the experimental “target space,” shifting attention from viral proteins alone toward the cellular machinery that viruses exploit to replicate and spread.

Rather than relying solely on direct-acting antivirals, the researchers employed systematic loss- and function-focused approaches to map host genes required for viral propagation. This design aims to identify vulnerability points where interference with host pathways can suppress infection, potentially reducing the risk that viral mutations will quickly undermine efficacy.

The team reports the identification of unique host-directed drugs with anti–SARS-CoV-2 activity. These candidates were highlighted based on their ability to modulate infection-associated phenotypes, consistent with pharmacological engagement of host processes rather than direct disruption of viral components.

Beyond drug candidates, the study also delineates pro-viral signalling pathways—cellular cascades that appear to promote productive infection. By integrating screening outputs with pathway-level interpretation, the authors connect specific gene sets to signalling programs that SARS-CoV-2 may activate or exploit during the viral life cycle.

Technically, the work emphasizes that host-directed hits can be evaluated through convergence of multiple lines of evidence: infection readouts, pathway enrichment, and drug–target logic that supports a mechanistic interpretation. Such triangulation strengthens the claim that the observed antiviral effects reflect pathway control rather than off-target toxicity.

The authors further discuss how these findings may guide more rational combination strategies. Pairing host-pathway modulators with existing antivirals could, in principle, yield more durable therapeutic responses by attacking infection from complementary angles—viral processes and host permissiveness.

Importantly, host-based approaches may offer resilience against viral antigenic drift. Since the targeted vulnerabilities are encoded in host biology, the mechanism does not depend exclusively on mutable viral sequences.

Taken together, the study positions genome-wide host screening as a practical pipeline for rapid antiviral discovery, providing both actionable candidate therapeutics and testable hypotheses for SARS-CoV-2 pro-viral signalling mechanisms.

These results arrive amid ongoing efforts to broaden the antiviral arsenal against emerging and re-emerging respiratory viruses. If validated in preclinical and clinical follow-ups, the identified host-directed drugs and pathway targets could expand the therapeutic landscape beyond conventional virus-centric approaches.